Abstract
Backgrounds/Aims
Methods
Results
Notes
Ethics Statement
The study was approved by the Institutional Review Board vide letter number AHF/02-35/2024 and informed consent was obtained from all the patients.
Data Availability
The data presented in this study are available upon reasonable request from the corresponding author.
Author Contributions
Conceptualization: AVK, AGS
Data curation: AVK, KP, AR, PGV
Formal analysis: AVK, SV
Investigation: AVK, AS, MA
Methodology: AVK, BM, MS, PNR, SI
Project administration: DNR
Resources: DNR
Software: AVK
Supervision: AGS
Validation: SKR
Writing - original draft: AVK, KP
Writing - review & editing: PNR, AGS
Supplementary Material
References
Table 1.
Variable | Patients (n=12) |
---|---|
Age (years) | 58.5 (41-71) |
Sex | |
Male | 10 (83.3) |
Female | 2 (16.7) |
Etiology of cirrhosis | |
MASH | 6 (50.0) |
HBV | 4 (33.4) |
HCV | 1 (8.3) |
Alcohol | 1 (8.3) |
Varices at baseline | |
None/grade I | 6 (50.0) |
Garde II | 5 (41.7) |
Grade III | 1 (8.3) |
Variceal eradication prior to atezo-bev | 3 (25.0) |
Median number of lesions | 3 (1-8) |
Largest lesion (cm) | 8 (4-16) |
Portal vein tumoral thrombosis | |
None | 5 (41.7) |
Vp2 | 1 (8.3) |
Vp3 | 2 (16.7) |
Vp4 | 4 (33.3) |
Extrahepatic spread | |
None | 10 (83.4) |
Lymph nodes | 1 (8.3) |
Bones | 1 (8.3) |
CTP class | |
A | 7 (58.3) |
B | 5 (41.7) |
BCLC stage | |
B | 5 (41.7) |
C | 7 (58.3) |
ECOG PS | |
0 | 10 (83.3) |
1 | 2 (16.7) |
Locoregional therapy | |
TARE (Y90) | 2 (16.7) |
Ablation | 1 (8.3) |
SBRT | 1 (8.3) |
None | 8 (66.7) |
Cumulative cycles of atezo-bev in all patients | 5 (3-12) |
Dose of bevacizumab | 800 (500-1,000) |
mRECIST | |
Complete response | 6 (50.0) |
Partial response | 6 (50.0) |
Adverse events to atezo-bev* | |
Grade 1 | |
Abdominal pain | 1 (8.3) |
Dizziness | 1 (8.3) |
Fatigue | 2 (16.7) |
Joint pains | 1 (8.3) |
Fever and myalgia | 1 (8.3) |
Mouth ulcers | 1 (8.3) |
Hoarseness | 1 (8.3) |
Grade 2 | |
Proteinuria | 1 (8.3) |
Hematuria | 1 (8.3) |
Herpes labialis | 1 (8.3) |
Penile ulceration | 1 (8.3) |
Grade 3 | |
Jaundice and ascites | 1 (8.3) |
Ascites | 1 (8.3) |
Variceal bleeding | 1 (8.3) |
AFP at diagnosis (ng/mL) | 116 (4.1-23,090.0) |
>400 | 2 (16.7) |
AFP Prior to LT/resection (n=6) | 4.85 (2.9-62.4) |
AFP >400 ng/mL | 0 (0.0) |
Washout period for those undergoing LT (days) | 89 (38-114) |
Right lobe graft (LDLT) | 4 (66.7) |
Cadaveric graft | 1 (8.3) |
Resection | 1 (8.3) |
Donor features of all LDLT recipients | |
Age (years) | 31.5 (21-48) |
Male/female | 3/1 |
GRWR | 0.95 (0.9-1.2) |
Relation to recipient, son/daughter/brother | 2/1/1 |
Post LT/resection complications† (out of 6 patients) | |
Grade 1 | |
Wound healing | 2 (33.3) |
Grade 2 | |
Pneumonia | 1 (16.6) |
Acute kidney injury | 1 (16.6) |
Grade 3b | |
Wound infection (burst abdomen) | 1 (16.6) |
Grade 5 | |
Sepsis with multiorgan dysfunction | 1 (16.6) |
Median follow up alive post LT/resection patients (months) | 10 (4-30) |
Values are presented as median (range) or number (%).
MASH, metabolic dysfunction associated steatohepatitis; HBV, hepatitis B virus; HCV, hepatitis C virus; atezo-bev, atezolizumab-bevacizumab; CTP, Child Turcotte Pugh; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; PS, performance status; TARE, transarterial radioembolization; SBRT, stereotactic body radiotherapy; mRECIST, modified response evaluation criteria in solid tumors; AFP, alpha-fetoprotein; LT, liver transplantation; LDLT, living donor liver transplantation; GRWR, graft-to-recipient ratio.